New Drug Shows Promise in Treating Obstructive Sleep Apnea

A recent clinical trial has indicated that sulthiame, a drug traditionally used to treat epilepsy, may significantly improve symptoms of obstructive sleep apnea (OSA). Conducted by researchers at the University of Gothenburg in Sweden, the study involved 298 adults diagnosed with moderate to severe OSA across four European countries: Belgium, Czechia, France, Germany, and Spain. Participants were randomly assigned to receive either sulthiame at varying doses (100 mg, 200 mg, or 300 mg) or a placebo. Results demonstrated that those taking the higher doses of sulthiame experienced up to a 47% reduction in breathing interruptions during sleep and improved overnight oxygen levels compared to the placebo group.

ScienceAlert

Sulthiame appears to enhance the body's control over breathing, potentially reducing the likelihood of airway collapse during sleep, which is a primary cause of OSA. This pharmacological approach could offer a new avenue for treatment, especially for patients who struggle with the conventional continuous positive airway pressure (CPAP) devices, which are often uncomfortable and lead to high discontinuation rates.

UsNews and World ReportScienceAlert

Obstructive sleep apnea is characterized by repeated collapses of the upper airway during sleep, leading to disrupted breathing and decreased oxygen levels. If left untreated, OSA can increase the risk of serious health issues, including hypertension, heart disease, stroke, and type 2 diabetes. Current treatments primarily involve CPAP machines, but many patients find them difficult to use consistently.

UsNews and World Report

Jan Hedner, the lead researcher and a senior professor of pulmonary medicine, expressed optimism about the findings, stating, "We have been working on this treatment strategy for a long time, and the results show that sleep apnea can indeed be influenced pharmacologically." He emphasized the need for larger and longer studies to assess the long-term efficacy and safety of sulthiame for broader patient populations.

UsNews and World Report

Despite the promising results, some experts caution against premature conclusions. The drug is still considered investigational in the U.S. and Canada, and further research is necessary to confirm its safety and effectiveness across diverse patient demographics. Critics also highlight that while sulthiame may address some underlying issues of OSA, it does not replace the need for comprehensive treatment strategies that include lifestyle changes and other interventions.

UsNews and World Report

The findings from this trial, published in *The Lancet*, pave the way for future research aimed at validating sulthiame's efficacy in larger populations and potentially gaining regulatory approval for its use in treating sleep apnea. As the prevalence of sleep apnea continues to rise, effective and accessible treatment options like sulthiame could significantly improve patient outcomes.

UsNews and World Report

• “It feels like a breakthrough, and we now look forward to larger and longer studies to determine whether the effect is sustained over time and whether the treatment is safe for broader patient groups.” — Jan Hedner, Senior Professor of Pulmonary Medicine, University of Gothenburg

ScienceAlert

• “These findings introduce a new individualized pharmacotherapy in patients with sleep disordered breathing,” — Jan Hedner and colleagues, University of Gothenburg

ScienceAlert